Epigenetic Therapies in Triple-Negative Breast Cancer: Concepts, Visions, and Challenges
Breast cancer, the most frequent malignancy in women worldwide, is a molecularly and clinically very heterogeneous disease. Triple-negative breast cancer is defined by the absence of hormone receptor and growth factor receptor ERBB2/HER2 expression. It is characterized by a more aggressive course of...
Gespeichert in:
| Veröffentlicht in: | Cancers 2024-06, Vol.16 (12), p.2164 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 12 |
| container_start_page | 2164 |
| container_title | Cancers |
| container_volume | 16 |
| creator | Lehmann, Ulrich |
| description | Breast cancer, the most frequent malignancy in women worldwide, is a molecularly and clinically very heterogeneous disease. Triple-negative breast cancer is defined by the absence of hormone receptor and growth factor receptor ERBB2/HER2 expression. It is characterized by a more aggressive course of disease and a shortage of effective therapeutic approaches. Hallmarks of cancer cells are not only genetic alterations, but also epigenetic aberrations. The most studied and best understood alterations are methylation of the DNA base cytosine and the covalent modification of histone proteins. The reversibility of these covalent modifications make them attractive targets for therapeutic intervention, as documented in numerous ongoing clinical trials. Epidrugs, targeting DNA methylation and histone modifications, might offer attractive new options in treating triple-negative breast cancer. Currently, the most promising options are combination therapies in which the epidrug increases the efficiency of immuncheckpoint inhibitors. This review focusses exclusively on DNA methylation and histone modifications. In reviewing the knowledge about epigenetic therapies in breast cancer, and especially triple-negative breast cancer, the focus is on explaining concepts and raising awareness of what is not yet known and what has to be clarified in the future. |
| doi_str_mv | 10.3390/cancers16122164 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11202282</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A799454087</galeid><sourcerecordid>A799454087</sourcerecordid><originalsourceid>FETCH-LOGICAL-g333t-73a281e617589d31d8218b8231cf659374d8410bab7ef77be634ff84154bf4923</originalsourceid><addsrcrecordid>eNptkU1v1DAQhi0EolXpmRuKxIUDaW2P1x9cUIlaqFSVy4K4WU4yybrK2sHOVuLf435Qtaj2YUbjZ97ROybkLaNHAIYedy50mDKTjHMmxQuyz6nitZRGvHyU75HDnK9oOQBMSfWa7IE2XGlF98mv09mPGHDxXbXeYHKzx1z5UK2TnyesL3F0i7_G6ktCl5equZ35qWpiifOSP1Y_ffYxlMSFvmo2bpowjJjfkFeDmzIe3scD8uPsdN18qy--fz1vTi7qEQCWWoHjmqFkaqVND6zXnOlWc2DdIFcGlOi1YLR1rcJBqRYliGEopZVoB2E4HJDPd7rzrt1i32FYkpvsnPzWpT82Om-fvgS_sWO8toxxyrm-Ufhwr5Di7x3mxW597nCaXMC4yxbKIjUFI01B3_-HXsVdCsXfLVV2ygr5QI1uQuvDEMvg7kbUnihjxEpQrQp19AxVbo9b38WAgy_1Jw3vHjt9sPjvM-Evt1mgOg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3072278180</pqid></control><display><type>article</type><title>Epigenetic Therapies in Triple-Negative Breast Cancer: Concepts, Visions, and Challenges</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>NCBI_PubMed Central（免费）</source><source>EZB Electronic Journals Library</source><creator>Lehmann, Ulrich</creator><creatorcontrib>Lehmann, Ulrich</creatorcontrib><description>Breast cancer, the most frequent malignancy in women worldwide, is a molecularly and clinically very heterogeneous disease. Triple-negative breast cancer is defined by the absence of hormone receptor and growth factor receptor ERBB2/HER2 expression. It is characterized by a more aggressive course of disease and a shortage of effective therapeutic approaches. Hallmarks of cancer cells are not only genetic alterations, but also epigenetic aberrations. The most studied and best understood alterations are methylation of the DNA base cytosine and the covalent modification of histone proteins. The reversibility of these covalent modifications make them attractive targets for therapeutic intervention, as documented in numerous ongoing clinical trials. Epidrugs, targeting DNA methylation and histone modifications, might offer attractive new options in treating triple-negative breast cancer. Currently, the most promising options are combination therapies in which the epidrug increases the efficiency of immuncheckpoint inhibitors. This review focusses exclusively on DNA methylation and histone modifications. In reviewing the knowledge about epigenetic therapies in breast cancer, and especially triple-negative breast cancer, the focus is on explaining concepts and raising awareness of what is not yet known and what has to be clarified in the future.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers16122164</identifier><identifier>PMID: 38927870</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Breast cancer ; Care and treatment ; Cells ; Clinical trials ; Cytosine ; Development and progression ; DNA ; DNA methylation ; DNA sequencing ; Enzymes ; Epigenetic inheritance ; Epigenetics ; ErbB-2 protein ; Gene expression ; Genes ; Genetic engineering ; Health aspects ; Histones ; Malignancy ; Methylation ; Molecular modelling ; Nucleotide sequence ; Nucleotide sequencing ; Proteins ; Review</subject><ispartof>Cancers, 2024-06, Vol.16 (12), p.2164</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 by the author. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0003-2350-6584</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11202282/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11202282/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27922,27923,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38927870$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lehmann, Ulrich</creatorcontrib><title>Epigenetic Therapies in Triple-Negative Breast Cancer: Concepts, Visions, and Challenges</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Breast cancer, the most frequent malignancy in women worldwide, is a molecularly and clinically very heterogeneous disease. Triple-negative breast cancer is defined by the absence of hormone receptor and growth factor receptor ERBB2/HER2 expression. It is characterized by a more aggressive course of disease and a shortage of effective therapeutic approaches. Hallmarks of cancer cells are not only genetic alterations, but also epigenetic aberrations. The most studied and best understood alterations are methylation of the DNA base cytosine and the covalent modification of histone proteins. The reversibility of these covalent modifications make them attractive targets for therapeutic intervention, as documented in numerous ongoing clinical trials. Epidrugs, targeting DNA methylation and histone modifications, might offer attractive new options in treating triple-negative breast cancer. Currently, the most promising options are combination therapies in which the epidrug increases the efficiency of immuncheckpoint inhibitors. This review focusses exclusively on DNA methylation and histone modifications. In reviewing the knowledge about epigenetic therapies in breast cancer, and especially triple-negative breast cancer, the focus is on explaining concepts and raising awareness of what is not yet known and what has to be clarified in the future.</description><subject>Breast cancer</subject><subject>Care and treatment</subject><subject>Cells</subject><subject>Clinical trials</subject><subject>Cytosine</subject><subject>Development and progression</subject><subject>DNA</subject><subject>DNA methylation</subject><subject>DNA sequencing</subject><subject>Enzymes</subject><subject>Epigenetic inheritance</subject><subject>Epigenetics</subject><subject>ErbB-2 protein</subject><subject>Gene expression</subject><subject>Genes</subject><subject>Genetic engineering</subject><subject>Health aspects</subject><subject>Histones</subject><subject>Malignancy</subject><subject>Methylation</subject><subject>Molecular modelling</subject><subject>Nucleotide sequence</subject><subject>Nucleotide sequencing</subject><subject>Proteins</subject><subject>Review</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkU1v1DAQhi0EolXpmRuKxIUDaW2P1x9cUIlaqFSVy4K4WU4yybrK2sHOVuLf435Qtaj2YUbjZ97ROybkLaNHAIYedy50mDKTjHMmxQuyz6nitZRGvHyU75HDnK9oOQBMSfWa7IE2XGlF98mv09mPGHDxXbXeYHKzx1z5UK2TnyesL3F0i7_G6ktCl5equZ35qWpiifOSP1Y_ffYxlMSFvmo2bpowjJjfkFeDmzIe3scD8uPsdN18qy--fz1vTi7qEQCWWoHjmqFkaqVND6zXnOlWc2DdIFcGlOi1YLR1rcJBqRYliGEopZVoB2E4HJDPd7rzrt1i32FYkpvsnPzWpT82Om-fvgS_sWO8toxxyrm-Ufhwr5Di7x3mxW597nCaXMC4yxbKIjUFI01B3_-HXsVdCsXfLVV2ygr5QI1uQuvDEMvg7kbUnihjxEpQrQp19AxVbo9b38WAgy_1Jw3vHjt9sPjvM-Evt1mgOg</recordid><startdate>20240607</startdate><enddate>20240607</enddate><creator>Lehmann, Ulrich</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2350-6584</orcidid></search><sort><creationdate>20240607</creationdate><title>Epigenetic Therapies in Triple-Negative Breast Cancer: Concepts, Visions, and Challenges</title><author>Lehmann, Ulrich</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g333t-73a281e617589d31d8218b8231cf659374d8410bab7ef77be634ff84154bf4923</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Breast cancer</topic><topic>Care and treatment</topic><topic>Cells</topic><topic>Clinical trials</topic><topic>Cytosine</topic><topic>Development and progression</topic><topic>DNA</topic><topic>DNA methylation</topic><topic>DNA sequencing</topic><topic>Enzymes</topic><topic>Epigenetic inheritance</topic><topic>Epigenetics</topic><topic>ErbB-2 protein</topic><topic>Gene expression</topic><topic>Genes</topic><topic>Genetic engineering</topic><topic>Health aspects</topic><topic>Histones</topic><topic>Malignancy</topic><topic>Methylation</topic><topic>Molecular modelling</topic><topic>Nucleotide sequence</topic><topic>Nucleotide sequencing</topic><topic>Proteins</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lehmann, Ulrich</creatorcontrib><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Biological Sciences</collection><collection>ProQuest_Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lehmann, Ulrich</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Epigenetic Therapies in Triple-Negative Breast Cancer: Concepts, Visions, and Challenges</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2024-06-07</date><risdate>2024</risdate><volume>16</volume><issue>12</issue><spage>2164</spage><pages>2164-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Breast cancer, the most frequent malignancy in women worldwide, is a molecularly and clinically very heterogeneous disease. Triple-negative breast cancer is defined by the absence of hormone receptor and growth factor receptor ERBB2/HER2 expression. It is characterized by a more aggressive course of disease and a shortage of effective therapeutic approaches. Hallmarks of cancer cells are not only genetic alterations, but also epigenetic aberrations. The most studied and best understood alterations are methylation of the DNA base cytosine and the covalent modification of histone proteins. The reversibility of these covalent modifications make them attractive targets for therapeutic intervention, as documented in numerous ongoing clinical trials. Epidrugs, targeting DNA methylation and histone modifications, might offer attractive new options in treating triple-negative breast cancer. Currently, the most promising options are combination therapies in which the epidrug increases the efficiency of immuncheckpoint inhibitors. This review focusses exclusively on DNA methylation and histone modifications. In reviewing the knowledge about epigenetic therapies in breast cancer, and especially triple-negative breast cancer, the focus is on explaining concepts and raising awareness of what is not yet known and what has to be clarified in the future.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38927870</pmid><doi>10.3390/cancers16122164</doi><orcidid>https://orcid.org/0000-0003-2350-6584</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2024-06, Vol.16 (12), p.2164 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11202282 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; NCBI_PubMed Central（免费）; EZB Electronic Journals Library |
| subjects | Breast cancer Care and treatment Cells Clinical trials Cytosine Development and progression DNA DNA methylation DNA sequencing Enzymes Epigenetic inheritance Epigenetics ErbB-2 protein Gene expression Genes Genetic engineering Health aspects Histones Malignancy Methylation Molecular modelling Nucleotide sequence Nucleotide sequencing Proteins Review |
| title | Epigenetic Therapies in Triple-Negative Breast Cancer: Concepts, Visions, and Challenges |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T14%3A51%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Epigenetic%20Therapies%20in%20Triple-Negative%20Breast%20Cancer:%20Concepts,%20Visions,%20and%20Challenges&rft.jtitle=Cancers&rft.au=Lehmann,%20Ulrich&rft.date=2024-06-07&rft.volume=16&rft.issue=12&rft.spage=2164&rft.pages=2164-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers16122164&rft_dat=%3Cgale_pubme%3EA799454087%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3072278180&rft_id=info:pmid/38927870&rft_galeid=A799454087&rfr_iscdi=true |